Amgen, a major player in the biotech sector, has recently been subjected to broad ranging coverage from various investment entities. Guggenheim and Argus Research offered insights on the company, reinforcing its relevancy in the investment landscape. The company's stock is garnering significant attention from investors, as noted by Freedom Capital downgrading their rating to 'Hold'. The company's recent participation in Citi's 2026 virtual oncology summit offered chances to watch Amgen's strategic directions. It made headlines as its stock hit a 52-week high and filed for Automatic Mixed Securities Shelf Registration. Excitement builds around expanded EU use of UPLIZNA, their autoimmune disease drug which could be a game-changer. Their financial performance remains robust with Q4 financial results exceeding estimates and consensus recommendations indicating a 'moderate buy'. AMGN’s new drug reportedly has promising data, as claimed by Jim Cramer. Their innovative actions, highlighted by a heavy investment in a new state-of-the-art science and innovation center, signify their commitment to continue driving development forward in the biotech landscape. They also announced a $650M expansion of US manufacturing, creating hundreds of jobs while announcing steps to lower the cost of medicine for American patients.
Amgen AMGN News Analytics from Tue, 02 Sep 2025 07:00:00 GMT to Sat, 14 Feb 2026 11:41:05 GMT -
Rating 6
- Innovation 8
- Information 9
- Rumor -5
